Vaso Stock Price, News & Analysis

Vaso Corporation (OTCQX: VASO) is a diversified medical technology and information technology company with several distinct but related specialties. According to company disclosures, Vaso focuses on managed IT systems and services, healthcare professional sales services, and the design, manufacture, and sale of proprietary medical devices. The company is headquartered in Plainview, New York, and operates through three wholly owned subsidiaries that together form its core business segments.

Vaso is frequently described in its public communications as a MedTech business with a diversified portfolio in network and healthcare IT services, professional sales services, and proprietary medical products. Its structure allows it to participate in multiple parts of the healthcare ecosystem, from medical equipment sales representation to IT connectivity and medical device manufacturing. The company’s common stock trades on the OTCQX market under the symbol VASO.

Business Segments and Subsidiaries

VasoTechnology, Inc. represents the company’s information technology and managed connectivity operations. Company materials state that VasoTechnology provides network and IT services through business units that include NetWolves Network Services LLC, a managed network services provider with an extensive, proprietary service platform serving a broad base of customers. VasoTechnology is also associated with healthcare IT and network services that support healthcare provision and other sectors.

Vaso has disclosed that VasoHealthcare IT Corp. was a business unit within its information technology segment, operating as a healthcare IT application value added reseller. VasoHealthcare IT provided imaging information technology to hospitals and healthcare providers and acted as a national value added reseller of radiology information systems (RIS), picture archiving and communication systems (PACS), and other software solutions, along with related implementation, management, and support services. In November 2025, Vaso announced an agreement, subject to certain conditions, to sell VasoHealthcare IT Corp. to Nano-X Imaging Ltd., following a strategic review of its lines of business.

Vaso Diagnostics, Inc. d/b/a VasoHealthcare is the company’s professional sales services arm. Public releases describe VasoHealthcare as the operating subsidiary responsible for the exclusive sales representation of GE HealthCare diagnostic imaging and ultrasound products in certain market segments in the United States. VasoHealthcare’s role is to represent GE HealthCare’s portfolio of diagnostic imaging and ultrasound products and services, including CT, MR, molecular imaging, X-ray, mammography, and interventional guided solutions systems, as well as associated service and financial offerings, under a long-term sales representation agreement.

In December 2025, Vaso announced that VasoHealthcare had signed an amendment to its sales representation agreement with GE HealthCare to extend the term of the agreement through December 31, 2030. This was identified as the fifth extension of the agreement, originally begun in May 2010, and the company highlighted that the relationship would ultimately span over 20 years. The extension allows VasoHealthcare to continue representing GE HealthCare’s diagnostic imaging and ultrasound portfolio and is presented as reinforcing a longstanding collaboration focused on advancing diagnostic imaging and ultrasound solutions across the United States.

VasoMedical, Inc. manages and coordinates the design, manufacture, and sale of proprietary medical equipment and software, and operates the company’s overseas assets, including China-based subsidiaries. Company descriptions state that VasoMedical is the designer and manufacturer of proprietary medical devices including Biox series devices and is the developer and operator of the ARCS cloud-based software-as-a-service (SaaS) platform. Vaso has also noted that ARCS software subscription revenue is a component of its equipment segment performance.

Core Activities and Industry Positioning

Across these subsidiaries, Vaso describes itself as a leading human capital, information technology, and MedTech business with a focus on healthcare professional sales services, network and IT services across sectors, and proprietary medical products. The company emphasizes its role in managed IT systems and services, including healthcare software solutions and network connectivity services, professional sales services for medical equipment, and the design, manufacture, and sale of proprietary medical devices.

In its public financial communications, Vaso refers to three primary business segments: an IT segment focused on network and healthcare IT services; a professional sales service segment centered on medical equipment sales representation; and an equipment segment focused on proprietary medical devices and related software. The company notes that subscription revenues, including those from software offerings such as ARCS, are a significant portion of total revenue, and that deferred revenue from its professional sales service segment and backlogs in its IT and equipment segments contribute to revenue stability and financial visibility.

Relationship with GE HealthCare

A notable aspect of Vaso’s business model is its long-term relationship with GE HealthCare through VasoHealthcare. The company highlights that VasoHealthcare is the professional sales service arm for GE HealthCare’s diagnostic imaging and ultrasound products in certain U.S. market segments. Under the extended agreement through 2030, VasoHealthcare continues to represent GE HealthCare’s portfolio of diagnostic imaging and ultrasound systems, along with associated service and financial offerings. Public statements from both companies emphasize that this collaboration aims to support healthcare providers, including community hospitals, outpatient imaging centers, and specialty practices, and to bring GE HealthCare technology to the point of care.

Information Technology and Managed Connectivity

Within the IT segment, VasoTechnology’s activities include managed network services and healthcare IT solutions. NetWolves Network Services LLC is described as a managed network services provider with an extensive, proprietary service platform serving a broad base of customers. VasoHealthcare IT, prior to the announced divestiture, was characterized as a national value added reseller of RIS, PACS, and other healthcare software solutions, offering implementation, management, and support services. Company communications also describe VasoTechnology as an information technology and managed connectivity leader serving customers in healthcare provision and other sectors.

Medical Devices and SaaS Platforms

Through VasoMedical, Vaso engages in the design, manufacture, and sale of proprietary medical devices and software. The company specifically identifies Biox series devices as part of its proprietary medical device portfolio and notes that it develops and operates the ARCS cloud-based SaaS platform. Vaso has reported that ARCS software subscription revenue contributes to its equipment segment, and that VasoMedical also operates overseas assets, including subsidiaries based in China.

Corporate Governance and Shareholder Matters

Vaso’s SEC filings indicate an ongoing program of shareholder engagement and corporate governance. For example, the company’s definitive proxy statement for its 2025 annual meeting outlines proposals including the election of Class II directors, an advisory “Say on Pay” vote on executive compensation, and an advisory “Say When on Pay” vote on the frequency of future Say on Pay votes. A subsequent Form 8-K filing reported the voting results, including the election of directors and shareholder support for holding Say on Pay votes every three years, which the Board adopted as its policy.

The company also holds annual shareholder meetings and provides proxy materials and annual reports through established channels. These activities, along with periodic Form 8-K filings on material events such as the planned sale of VasoHealthcare IT Corp., form part of the company’s regulatory and investor communication framework.

Financial Reporting and Use of Non-GAAP Measures

In its periodic financial news releases, Vaso presents summarized financial information for its IT, professional sales service, and equipment segments. The company also discloses the use of Adjusted EBITDA, defined as earnings (loss) before interest, taxes, depreciation and amortization, and non-cash stock-based compensation, as a non-GAAP financial measure. Vaso states that it utilizes Adjusted EBITDA to evaluate performance internally and that securities analysts and investors frequently use this measure in evaluating companies in its industry. The company notes that Adjusted EBITDA is not a measure of financial performance under U.S. GAAP, should not be considered a substitute for GAAP measures such as net income or operating income, and has limitations as an analytical tool.

Stock and Market Context

Vaso Corporation’s common stock is quoted on the OTCQX market under the symbol VASO. The company describes itself as a MedTech and information technology business with a diversified portfolio across healthcare professional sales services, network and IT services, and proprietary medical products. Its operations span managed network services, healthcare IT solutions, medical equipment sales representation, and proprietary medical devices and software, organized through its three wholly owned subsidiaries: VasoTechnology, VasoHealthcare, and VasoMedical.